ENZ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ENZ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-10-31), Enzo Biochem's current share price is $1.15. Enzo Biochem's Cyclically Adjusted Revenue per Share for the quarter that ended in Jul. 2024 was $2.05. Enzo Biochem's Cyclically Adjusted PS Ratio for today is 0.56.
The historical rank and industry rank for Enzo Biochem's Cyclically Adjusted PS Ratio or its related term are showing as below:
During the past years, Enzo Biochem's highest Cyclically Adjusted PS Ratio was 4.64. The lowest was 0.48. And the median was 1.29.
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Enzo Biochem's adjusted revenue per share data for the three months ended in Jul. 2024 was $0.146. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $2.05 for the trailing ten years ended in Jul. 2024.
The historical data trend for Enzo Biochem's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enzo Biochem Annual Data | |||||||||||||||||||||
Trend | Jul15 | Jul16 | Jul17 | Jul18 | Jul19 | Jul20 | Jul21 | Jul22 | Jul23 | Jul24 | |||||||||||
Cyclically Adjusted PS Ratio | Get a 7-Day Free Trial | 0.99 | 1.33 | 0.99 | 0.67 | 0.56 |
Enzo Biochem Quarterly Data | ||||||||||||||||||||
Oct19 | Jan20 | Apr20 | Jul20 | Oct20 | Jan21 | Apr21 | Jul21 | Oct21 | Jan22 | Apr22 | Jul22 | Oct22 | Jan23 | Apr23 | Jul23 | Oct23 | Jan24 | Apr24 | Jul24 | |
Cyclically Adjusted PS Ratio | Get a 7-Day Free Trial | 0.67 | 0.62 | 0.59 | 0.50 | 0.56 |
For the Diagnostics & Research subindustry, Enzo Biochem's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Diagnostics & Research industry and Healthcare sector, Enzo Biochem's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Enzo Biochem's Cyclically Adjusted PS Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Enzo Biochem's Cyclically Adjusted PS Ratio for today is calculated as
Cyclically Adjusted PS Ratio | = | Share Price | / | Cyclically Adjusted Revenue per Share |
= | 1.15 | / | 2.05 | |
= | 0.56 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enzo Biochem's Cyclically Adjusted Revenue per Share for the quarter that ended in Jul. 2024 is calculated as:
For example, Enzo Biochem's adjusted Revenue per Share data for the three months ended in Jul. 2024 was:
Adj_RevenuePerShare | = | Revenue per Share | / | CPI of Jul. 2024 (Change) | * | Current CPI (Jul. 2024) |
= | 0.146 | / | 132.7078 | * | 132.7078 | |
= | 0.146 |
Current CPI (Jul. 2024) = 132.7078.
Enzo Biochem Quarterly Data
Revenue per Share | CPI | Adj_RevenuePerShare | |
201410 | 0.557 | 100.176 | 0.738 |
201501 | 0.513 | 98.604 | 0.690 |
201504 | 0.524 | 99.824 | 0.697 |
201507 | 0.558 | 100.691 | 0.735 |
201510 | 0.545 | 100.346 | 0.721 |
201601 | 0.528 | 99.957 | 0.701 |
201604 | 0.572 | 100.947 | 0.752 |
201607 | 0.565 | 101.524 | 0.739 |
201610 | 0.568 | 101.988 | 0.739 |
201701 | 0.567 | 102.456 | 0.734 |
201704 | 0.584 | 103.167 | 0.751 |
201707 | 0.548 | 103.278 | 0.704 |
201710 | 0.573 | 104.070 | 0.731 |
201801 | 0.557 | 104.578 | 0.707 |
201804 | 0.536 | 105.708 | 0.673 |
201807 | 0.482 | 106.324 | 0.602 |
201810 | 0.451 | 106.695 | 0.561 |
201901 | 0.409 | 106.200 | 0.511 |
201904 | 0.413 | 107.818 | 0.508 |
201907 | 0.438 | 108.250 | 0.537 |
201910 | 0.425 | 108.577 | 0.519 |
202001 | 0.408 | 108.841 | 0.497 |
202004 | 0.354 | 108.173 | 0.434 |
202007 | 0.409 | 109.318 | 0.497 |
202010 | 0.598 | 109.861 | 0.722 |
202101 | 0.655 | 110.364 | 0.788 |
202104 | 0.672 | 112.673 | 0.791 |
202107 | 0.510 | 115.183 | 0.588 |
202110 | 0.547 | 116.696 | 0.622 |
202201 | 0.702 | 118.619 | 0.785 |
202204 | 0.538 | 121.978 | 0.585 |
202207 | -1.111 | 125.002 | -1.179 |
202210 | 0.146 | 125.734 | 0.154 |
202301 | 0.154 | 126.223 | 0.162 |
202304 | 0.152 | 127.992 | 0.158 |
202307 | 0.180 | 128.974 | 0.185 |
202310 | 0.156 | 129.810 | 0.159 |
202401 | 0.169 | 130.124 | 0.172 |
202404 | 0.157 | 132.289 | 0.157 |
202407 | 0.146 | 132.708 | 0.146 |
Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Enzo Biochem (NYSE:ENZ) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Thank you for viewing the detailed overview of Enzo Biochem's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Steven J Pully | director | 9800 RICHMOND AVE, SUITE 700, HOUSTON TX 77042 |
James G. Wolf | 10 percent owner | 105, FLYWAY DRIVE, KIAWAH ISLAND SC 29455 |
Hamid Erfanian | officer: Chief Executive Officer | 527 MADISON AVENUE, NEW YORK NY 10022 |
Patricia Eckert | officer: Interim CFO | C/O ENZO BIOCHEM, INC., 81 EXECUTIVE BLVD, SUITE 3, FARMINGDALE NY 11735 |
Kara Cannon | officer: Chief Operating Officer | 527 MADISON AVE, NEW YORK NY 10022 |
Bradley Louis Radoff | director | 2727 KIRBY DRIVE, UNIT 29L, HOUSTON TX 77098 |
David Bench | officer: CHIEF FINANCIAL OFFICER | ENZO BIOCHEM, INC., 527 MADISON AVENUE, NEW YORK NY 10022 |
Harbert Discovery Fund, Lp | 10 percent owner | HARBERT DISCOVERY FUND GP, LLC, 2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203 |
Ian B. Walters | director | ENZO BIOCHEM, INC., 527 MADISON AVENUE, NEW YORK NY 10022 |
Mary Tagliaferri | director | 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158 |
Clemens Peter J Iv | 10 percent owner | 2383 N. BERRY'S CHAPEL RD., FRANKLIN TN 37069 |
Rebecca J. Fischer | director | ENZO BIOCHEM, INC., 527 MADISON AVENUE, NEW YORK NY 10022 |
Fabian Blank | 10 percent owner, other: See Remarks | ROEMERSTRASSE 6, BAD BERTRICH 2M 56864 |
Harbert Management Corp | 10 percent owner | 2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203 |
Harbert Discovery Co-investment Fund I Gp, Llc | 10 percent owner | 2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203 |
From GuruFocus
By GuruFocus Research • 02-10-2024
By Marketwired • 11-06-2023
By GuruFocus Research • 02-14-2024
By GuruFocus Research • 02-10-2024
By Value_Insider Value_Insider • 12-08-2022
By GuruFocus Research • 02-10-2024
By GuruFocus Research • 02-10-2024
By sperokesalga sperokesalga • 03-21-2023
By GuruFocus Research • 02-10-2024
By GuruFocus Research • 02-10-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.